About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 536 record(s)
Req # A-2022-001619
Adverse Drug Reaction (ADR). Report number: 001026724.Organization: Health Canada
July 2023
Req # A-2022-001624
Adverse Drug Reactions (ADRs). Report numbers: E2B_05127159, E2B_05189982, E2B_05043162, E2B_05096839, E2B_02413518, 000927984, E2B_03466359, E2B_02747441, E2B_05785361, 001010550.Organization: Health Canada
July 2023
Req # A-2022-001657
Adverse Drug Reactions (ADRs). Report numbers: 001013659, E2B_02989790, E2B_05372962, E2B_04181634, E2B_04181139, E2B_03794891, E2B_03293332, E2B_05740582, E2B_05799925, E2B_05738680.Organization: Health Canada
July 2023
Req # A-2022-001686
Adverse Drug Reactions (ADRs). Report numbers: 001021717, E2B_05824479, E2B_05789236, E2B_03383022, E2B_02732043, E2B_01465889, E2B_05752679, E2B_05468464, E2B_02249603, E2B_05874043.Organization: Health Canada
July 2023
Req # A-2023-000004
Adverse Drug Reaction (ADR) for PANTOPRAZOLE SODIUM. Report number: E2B_06055213. ADR for ADDERALL XR. Report number: 001024861. ADRs for MESALAZINE. Report numbers: E2B_06032558, E2B_06033711, E2B_06117931, E2B_06029464, 001025065, 001024500,…Organization: Health Canada
July 2023
Req # A-2023-000005
Adverse Drug Reactions (ADRs) for C1 ESTERASE INHIBITOR (HUMAN). Report numbers: E2B_06059052, E2B_06083180, E2B_06058994, E2B_06059067, E2B_06057820, E2B_06059038, E2B_06059475, E2B_06076092, E2B_06066944, E2B_06029786.Organization: Health Canada
July 2023
Req # A-2023-000010
Adverse Drug Reaction (ADR). Report number: E2B_03816205.Organization: Health Canada
July 2023
Req # A-2023-000031
Adverse Drug Reactions (ADRs) for SOLIRIS. Report numbers: 001026765, E2B_06035783, E2B_06090605.Organization: Health Canada
July 2023
Req # A-2023-000041
Adverse Drug Reactions (ADRs). Report numbers: 001026369, E2B_06086821, E2B_06083913.Organization: Health Canada
July 2023
Req # A-2023-000044
Adverse Drug Reactions (ADRs). Report numbers: 000934571, E2B_03683830, 000936713, E2B_05008901, E2B_05011872, 000939394, 000940032, 000940033, 000941197, 000944869.Organization: Health Canada
July 2023